Complete FcγRIIIa Effector Function Analysis for mAb Biologics with High (V158) and Low (F158) Affinity Reporter Bioassays.
In this webinar, you will learn how ADCC Reporter Bioassays are:
- Reflective of MOA
- Well controlled with regard to precision, accuracy and reproducibility
- Usable as a QC lot-release assay
Summary
ADCC is an important MOA for therapeutic antibodies and efficacy can correlate with the population of high affinity (V158) and low affinity (F158) FcγRIIIa. To better assess activation of ADCC by a therapeutic antibody, we have developed surrogate ADCC Reporter Bioassays with either the high affinity or low affinity FcγRIIIa through use of engineered Jurkat cells. Activation of either FcγRIIIa will result in activation of the NFAT pathway as judged by a luciferase reporter.
Promega reporter-based ADCC assays quantitatively measure Fc effector function for therapeutic antibodies using ADCC as MOA. We will discuss the benefits of using frozen, thaw-and-use cells for convenience, time and cost savings, and improved run-to-run assay variation. We will discuss the ease of use of the assays and how they can provide precise, accurate and reproducible data.
Speaker
Richard Somberg, PhD
Strategic Collaborations Manager
Promega Corporation
Richard is a Strategic Collaborations Manager at Promega and part of a team focused on building strategic relationships with pharmaceutical and biotech companies via early access to technologies, custom assay services, and collaborative support. Prior to his position at Promega, Dr. Somberg worked at Life Technologies, where he led product development and service efforts in biochemical and cell-based assays for key target classes in drug discovery. He completed post-doctoral studies at the University of Pennsylvania, received his Ph.D. in immunology from Purdue University, and a Bachelor of Science in genetics and development from the University of Illinois.